My biggest complaint with them is that they are basing their entire valuation on the market potential for a single year of sales of 530. No mention of 188, 514 or M&A target potential. Either they have a short agenda or just perform very poor DD.
Now, you want to attack the drugs or the process and claim you do not believe it will get approval - fair game. But to assume it gets approved and is over valued? Please...
Zacks.com rated and placed "ANX" on the "strong buy" list ... now thats what I am talking about! : )
Finally some analysts that can see the light at the other end and aware of the much larger picture that requires a price target change that is much closer to $16 than the $7.50 and we could see quick run-ups now to the $7-8 mark any day now.
News 
Market Data 
Discover 
AI
